Welfare of Animals in Pharmaceutical Testing

Drug development requires safety testing in animals before human trials, involving millions of animals annually in studies that range from mildly stressful to highly painful.

Key Facts

The FDA requires animal safety testing for all new pharmaceutical compounds before human clinical trials
Approximately 25 million animals are used in pharmaceutical research globally each year
Repeated dosing toxicology studies can last 26 weeks or longer and involve significant welfare costs
The Draize eye irritancy test exposes rabbit eyes to test substances and is among the most controversial test methods
The 21st Century Cures Act in the US encouraged regulatory agencies to accept alternative data in some submissions
Companies including AstraZeneca, Roche, and Unilever have made public commitments to 3Rs implementation

Welfare Considerations

Pharmaceutical animal testing occupies a unique regulatory position: it is legally required as a condition of human drug approval, yet the science increasingly supports that animal models predict human outcomes poorly in many contexts. Regulatory acceptance of validated alternative methods lags behind the science, creating a system where animals suffer in tests with limited predictive value. The most impactful changes would come from regulatory reform at FDA, EMA, and equivalent agencies to formally accept validated non-animal methods, combined with sustained investment in developing and validating new approach methodologies.

What You Can Do

Support organisations like the NC3Rs and Humane Society that fund alternative methods development
Advocate for FDA and EMA regulatory reform to accept validated non-animal alternatives
Choose pharmaceutical companies that publish transparent animal use reduction data
Support academic research into organ-on-chip, organoid, and in silico models
Engage with regulatory comment processes when agencies propose animal testing guidelines